Abstract
The use of anthracyclines and anthrachinones in antineoplastic treatment is limited by the possible induction of irreversible cardiomyopathy [1, 2, 6, 7, 9]. In 1976, Daniels et al. observed a protective effect of subcutaneously administered verapamil in white rabbits [4]. Mullerleile et al. reported a beneficial effect of low-dose oral verapamil in 22 patients with different tumors treated with doxorubicin [10]. The aim of this study was to determine whether verapamil can protect against anthracycline cardiomyopathy without altering the clinical efficiency of the antineoplastic regimen in patients with acute myeloid leukemia (AML) [8, 10–12].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitoring by morphologic changes. Cancer Treat Rep 62: 865–872
Bristow MR, Billingham ME, Mason JW, Daniels JR (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62: 873–879
Büchner T, Urbanitz D, Hiddemann W et al. (1986) Akute myeloische Leukämie (AML) des Erwachsenen. Weiterentwicklung der Therapie auf der Basis klinischer Phase-II und Phase-III-Studien. Onkologie 9: 83–91
Daniels JR, Billingham ME, Gelbart A, Bristow MR (1976) Effect of verapamil and propanolol on adriamycin-induced cardiomyopathy in rabbits (Abstract). Circulation 53, 54 (Suppl II): 20
Freedman SB (1984) Pharmakokinetik von Calcium-Antagonisten. In: Althaus U (ed) Calcium-Antagonismus/Internat. Symposium on calcium antagonism. Universimed, Frankfurt, pp 30–49
Hofling B (1984) Die Anthracyclin-Kardiotoxizitat. Kehrer, Freiburg
Mason JW, Bristow MR, Billingham ME, Daniels JR (1978) Invasive and noninvasive methods assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62: 875
Klugmann S, Bartoldi Klugmann F, Decorti G, Gori D, Silvestri F, Camerini F (1981) Adriamycin experimental cardiomyopathy in Swiss mice. Different effects of two calcium antagonist drugs on ADM - cardiomyopathy. Pharmacol Res Commun 13: 769–776
Mather F, Simon RM, Clark GM, von Hoff DD (1987) Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 71: 609–613
Müllerleile U, Garbrecht M, Hanrath P, Langenstein BA, Bieber K, Bleifeld W, Hossfeld DK (1984) Mögliche Prävention der Adriamycin induzierten Kardiomyopathie durch Verapamil. Klin Wochenschr 62: 1032–1037
Polverino W, Basso A, Genovese A, Salvatore M, Pererone V, Muto P (1980) Verapamil and adriamycin cardiotoxicity. In: International symposium on calcium antagonism in cardiovascular therapy, Florence, October 2–4, 1980, pp 35–37
Rabkin SW, Godin DV (1985) Adriamycin cardiotoxicity and calcium entry blockers: the need for caution in the combination. Can J Cardiol 1 (5): 4–7
Villani V, Guindani A, Favalli L, Chiari C, Monti E, Piccinini F (1981) Role of cell calcium in the early and delayed cardiotoxicity of anthracyclines. Proc Am Assoc Cancer Res 22: 30
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kraft, J. et al. (1990). Effects of Verapamil on Anthracycline-Induced Cardiomyopathy: Preliminary Results of a Prospective Multicenter Trial. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_103
Download citation
DOI: https://doi.org/10.1007/978-3-642-74643-7_103
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50984-4
Online ISBN: 978-3-642-74643-7
eBook Packages: Springer Book Archive